ATE269098T1 - Verfahren zur vorbeugung von durch zyklosporine oder tacrolimus verursachter nierenvergiftung - Google Patents

Verfahren zur vorbeugung von durch zyklosporine oder tacrolimus verursachter nierenvergiftung

Info

Publication number
ATE269098T1
ATE269098T1 AT98952186T AT98952186T ATE269098T1 AT E269098 T1 ATE269098 T1 AT E269098T1 AT 98952186 T AT98952186 T AT 98952186T AT 98952186 T AT98952186 T AT 98952186T AT E269098 T1 ATE269098 T1 AT E269098T1
Authority
AT
Austria
Prior art keywords
tacrolimus
administration
patient
cyclosporin
pps
Prior art date
Application number
AT98952186T
Other languages
English (en)
Inventor
Gary E Striker
Lilliane Striker
Kenneth H Kortright
Original Assignee
Ivax Research Inc
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ivax Research Inc, Us Health filed Critical Ivax Research Inc
Application granted granted Critical
Publication of ATE269098T1 publication Critical patent/ATE269098T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Cephalosporin Compounds (AREA)
AT98952186T 1997-10-09 1998-10-09 Verfahren zur vorbeugung von durch zyklosporine oder tacrolimus verursachter nierenvergiftung ATE269098T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6294797P 1997-10-09 1997-10-09
PCT/US1998/021313 WO1999018961A1 (en) 1997-10-09 1998-10-09 Method of preventing nephrotoxicity caused by cyclosporins and tacrolimus

Publications (1)

Publication Number Publication Date
ATE269098T1 true ATE269098T1 (de) 2004-07-15

Family

ID=22045901

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98952186T ATE269098T1 (de) 1997-10-09 1998-10-09 Verfahren zur vorbeugung von durch zyklosporine oder tacrolimus verursachter nierenvergiftung

Country Status (23)

Country Link
US (1) US6187745B1 (de)
EP (1) EP1027053B1 (de)
JP (1) JP2001519392A (de)
KR (1) KR100515196B1 (de)
CN (1) CN1154492C (de)
AT (1) ATE269098T1 (de)
AU (1) AU748495B2 (de)
BR (1) BR9813860A (de)
CA (1) CA2304374A1 (de)
CZ (1) CZ297440B6 (de)
DE (1) DE69824619T2 (de)
DK (1) DK1027053T3 (de)
ES (1) ES2221714T3 (de)
HU (1) HUP0003904A3 (de)
IL (1) IL135235A0 (de)
NO (1) NO20001828L (de)
NZ (1) NZ503493A (de)
PL (1) PL191993B1 (de)
PT (1) PT1027053E (de)
RU (1) RU2191020C2 (de)
SK (1) SK285332B6 (de)
UA (1) UA65587C2 (de)
WO (1) WO1999018961A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001052867A1 (en) 2000-01-19 2001-07-26 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of pentosan polysulfate to treat certain conditions of the prostate
US6613083B2 (en) * 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
IL160761A0 (en) * 2001-10-19 2004-08-31 Isotechnika Inc Novel cyclosporin analog microemulsion preconcentrates
IL164185A0 (en) * 2002-04-16 2005-12-18 Fujisawa Pharmaceutical Co Pharmaceutical compositions containing trifluoromethylphenyl amide derivatives
ES2399277T3 (es) 2004-05-27 2013-03-27 Baxter International Inc. Procedimiento de tratamiento de trastornos hemorrágicos utilizando polisacáridos sulfatados
WO2010020423A2 (en) 2008-08-22 2010-02-25 Baxter Healthcare S.A. Methods for treating bleeding disorders
JP6393453B2 (ja) 2010-01-14 2018-09-19 バクスアルタ ゲーエムベーハー 出血性障害を治療するための方法及び組成物
US8871741B2 (en) * 2010-01-15 2014-10-28 Icahn School Of Medicine At Mount Sinai Inhibition of TNF-α induced activation of NFKB by pentosan polysulfate
CN102327282A (zh) * 2010-09-01 2012-01-25 吴洪 戊糖多聚硫酸酯用于制备治疗糖尿病肾病的药物中的用途
EP2734213B1 (de) 2011-07-19 2018-06-06 Baxalta GmbH Resorptionsförderer als additive zur verbesserung der oralen formulierung nicht-antikoagulierender sulfatierter polysaccharide
WO2013052380A2 (en) 2011-10-05 2013-04-11 Allergan, Inc. Compositions for enhancing nail health
EP2885642B1 (de) 2012-08-14 2019-05-15 Baxalta GmbH Verfahren und systeme zum screening von zusammensetzungen mit nicht gerinnenden sulfatierten polysacchariden
KR101760510B1 (ko) 2014-12-18 2017-07-21 가톨릭대학교 산학협력단 메트포민을 포함하는 면역억제제로 인한 신장 독성 완화용 조성물 및 이를 포함하는 면역질환 예방 또는 치료용 조성물
WO2016099214A1 (ko) * 2014-12-18 2016-06-23 가톨릭대학교 산학협력단 메트포민을 포함하는 면역억제제로 인한 신장 독성 완화용 조성물 및 이를 포함하는 면역질환 예방 또는 치료용 조성물
WO2016199161A2 (en) * 2015-06-12 2016-12-15 Swati Vishal Jajodia A composition comprising pentosan polysulfate sodium for use in treatment of bladder outlet obstruction and/or lower urinary tract symptoms

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3843241A1 (de) * 1988-12-22 1990-06-28 Skrezek Christian Nephroprotektive infusionsloesung
EP0466315A3 (en) 1990-05-30 1992-07-01 Larrian Gillespie Compositions containing xylan sulphates for affecting growth factor function and for inhibiting fibroblast proliferation
US5204329A (en) 1990-06-11 1993-04-20 Du Pont Merck Pharmaceutical Company Treatment of organ transplantation rejection
GB9116836D0 (en) * 1991-08-05 1991-09-18 Sandoz Ltd Organic compounds
US5605938A (en) * 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
RU2027471C1 (ru) * 1992-04-14 1995-01-27 Северо-Кавказский горно-металлургический институт Способ очистки суспензий и вибрационный фильтр-сгуститель для его осуществления
IT1277147B1 (it) * 1995-01-20 1997-11-04 Sigma Tau Ind Farmaceuti Uso della carnitina e i suoi derivati per ridurre gli effetti tossici della ciclosporina-a e di altri farmaci immunosoppressivi.
JPH08208489A (ja) * 1995-02-03 1996-08-13 L T T Kenkyusho:Kk 腎不全治療剤
US5643892A (en) * 1995-06-07 1997-07-01 Baker Norton Pharmaceuticals, Inc. Method of treating chronic progressive vascular diseases

Also Published As

Publication number Publication date
HK1026845A1 (en) 2000-12-29
CN1154492C (zh) 2004-06-23
UA65587C2 (en) 2004-04-15
AU9794398A (en) 1999-05-03
DE69824619D1 (de) 2004-07-22
CZ297440B6 (cs) 2006-12-13
KR100515196B1 (ko) 2005-09-16
EP1027053B1 (de) 2004-06-16
NO20001828D0 (no) 2000-04-07
AU748495B2 (en) 2002-06-06
CA2304374A1 (en) 1999-04-22
PL339774A1 (en) 2001-01-02
NZ503493A (en) 2001-11-30
CZ20001274A3 (cs) 2001-12-12
WO1999018961A1 (en) 1999-04-22
SK4672000A3 (en) 2001-09-11
CN1275080A (zh) 2000-11-29
EP1027053A1 (de) 2000-08-16
PL191993B1 (pl) 2006-08-31
DK1027053T3 (da) 2004-09-06
IL135235A0 (en) 2001-05-20
ES2221714T3 (es) 2005-01-01
HUP0003904A1 (hu) 2001-08-28
HUP0003904A3 (en) 2006-06-28
SK285332B6 (sk) 2006-11-03
DE69824619T2 (de) 2005-06-23
NO20001828L (no) 2000-05-15
EP1027053A4 (de) 2002-05-22
JP2001519392A (ja) 2001-10-23
US6187745B1 (en) 2001-02-13
RU2191020C2 (ru) 2002-10-20
KR20010030749A (ko) 2001-04-16
PT1027053E (pt) 2004-09-30
BR9813860A (pt) 2001-03-20

Similar Documents

Publication Publication Date Title
ATE269098T1 (de) Verfahren zur vorbeugung von durch zyklosporine oder tacrolimus verursachter nierenvergiftung
US6071918A (en) Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
Mahattanakul et al. Treatment of chronic inflammatory demyelinating polyneuropathy with cyclosporin-A.
CO5261582A1 (es) Composiciones de valdecoxib
CA2229282A1 (en) Use of hyaluronic acid as an immunosuppressant
CA2197554A1 (en) Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
JP2002523370A5 (de)
KR910019618A (ko) 발기부전증 치료용 제약 조성물
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
RU95101385A (ru) Продукты, содержащие g-csf и tnf связующие протеина
AU647463B2 (en) A method and a pharmaceutical preparation for treating pain
KR19980701720A (ko) 세스키테르펜 락톤 및 비타민 b 복합체를 함유하는 편두통 및 기타 질환 치료용 복합약
MY124465A (en) Reduction of infarct volume using citicoline
EP0190851B1 (de) Entzündungshemmende Zusammensetzung
Bissell et al. Longitudinal banded pigmentation of nails in primary adrenal insufficiency
Hagley et al. Suspected cross-reactivity of enalapril-and captopril-induced hepatotoxicity
Roy et al. Induction of theophylline toxicity and inhibition of clearance rates by ranitidine
KR900011461A (ko) 트립스타틴을 유효성분으로 하는 치료제
NO974486L (no) Lavdoserte "Ridogrel"-formuleringer samt anvendelse derav ved behandling av tarmbetennelse
BE1002255A5 (fr) Medicaments.
US20030064932A1 (en) Methods of treatment comprising administration of Substance P
Allgulander et al. Case report: A Delirious Abstinence Syndrome associated with Clorazepate (TranxilenR)
ATE91890T1 (de) Herstellung eines arzneimittels gegen arthritis und rheumatismus.
RU99112967A (ru) Способ лечения и профилактики дизентерии свиней
KR830008678A (ko) 진통 조성물

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1027053

Country of ref document: EP

REN Ceased due to non-payment of the annual fee